1. Breast Cancer NCCN Clinical Practice Guildliness In Oncology (2019 V2) 2. https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer 3. André F et al. (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New Eng...
[17]Cai Z, Wang J, Li Y, et al. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Sci China Life Sci 2023;66(1):94-109. [18]Brufsky AM, Dickler MN. Estrogen Receptor-Po...
[17]Cai Z, Wang J, Li Y, et al. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors. Sci China Life Sci...
In the present paper, we describe two clinical cases in which patients harboring PIK3CA-amplified TNBC received a targeted treatment with the mTOR-inhibitor everolimus and the PI3K-inhibitor alpelisib, respectively, with evidence of disease response on 18F-FDG positron-emission tomography...
Small Molecule Inhibitor-Mediated Chemotherapy Chemotherapy II. Indications Breast Cancer(PIK3CAmutation, HR positive, HER2 negative, metastatic) Alpelisib Follicular Lymphoma(relapsed) Copanlisib Duvelisib Idelalisib Chronic Lymphocytic Leukemia(relapsed or refractory) ...
Formisano,L., Balko, J.M., Estrada, M.V., Sanders, M.E., Juric, D., Solit, D., Berger,M.F., Won, H.H., et al. (2017). APhase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, withLetrozole in ER+/HER2 -Metastatic Breast Cancer. Clin Cancer Res 23, 26-34...
Formisano,L., Balko, J.M., Estrada, M.V., Sanders, M.E., Juric, D., Solit, D., Berger,M.F., Won, H.H., et al. (2017). APhase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, withLet...
1、FDA approves first PI3K inhibitor for breast cancer. Retrieved May 24,2019 2、SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation. ...
Jhaveri K, Kalinsky K, Bedard P, et al. A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer. Cancer Res. 2020;80(4_...
et al. Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-...